# of Displayed Technologies: 10 / 10

Applied Category Filter (Click To Remove): Drug Delivery


Categories

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Kudryashova, Elena
  • Licensing Officer: Flammang, Ann Marie

Multifunctional RNA Nanoparticles and Methods for Treating Cancer
TS-040289 — Three-way junction nanoparticles for delivery of tamoxifen and other therapeutics directly to tumor cells.
Most breast cancers express estrogen receptor alpha (ER α) and antagonists of ER α drugs, such as tamoxifen, have been widely used for their treatment. Unfortunately, up to half of all ER α -positive tumors have intrinsic or acquired endocrine therapy resistance. Recent studies b…
  • College: College of Pharmacy
  • Inventors: Zhang, Xiaoting; Guo, Peixuan
  • Licensing Officer: Flammang, Ann Marie

Novel compositions of nanoparticles for nucleic acid therapeutic delivery
TS-040254 — Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.
Lipid-based nanoparticles (LNPs) have been extensively utilized in nucleic acid delivery. However, there are a number of challenges associated with LNP formulation. It is difficult to make sub-100-nm LNPs with a high nucleic acid concentration by traditional self-assembly methods. LNP synthesis ty…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Method for treatment of diseases of central nervous system (CNS) and improvement of cognitive function by nanoscaffolds
TS-038406 — A novel method to improve CNS metabolism and overall cognitive function as well as reduce peripheral neurodeneration, through the use of nanomatrices with or without identified redefined delivery biologicals and/or insulin.
The central nervous system (CNS) can be implicated in a broad category of diseases in which the brain does not function as expected. Conditions may result from a metabolic disorder; damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or…
  • College: College of Arts & Sciences
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: Flammang, Ann Marie

Sustained Release Microparticles for the Treatment of Ocular Diseases
TS-038312 — A novel, intravitreal microparticle injection capable of controlled-release of protein therapies (including anti-VEGF) for tunable periods of 6-12 months after injection for the treatment of age-related macular degeneration.
Age-related macular degeneration (AMD) is the leading cause of blindness in individuals 65 and older and is the third leading cause of blindness worldwide. Wet AMD is characterized by abnormal growth of leaky blood vessels leading to damage to the macula of the retina resulting in vision loss and …
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

Immobilization of Biomolecules (Rubisco) by Self-Assembled Nanostructures
TS-037787 — Nanostructures that enhance the stability of biocatalysts that permit them to be utilized in scalable CO2 conversion processes
Carbon dioxide (CO2) and methane (CH4) are the two most abundant greenhouse gasses, trapping thermal radiation close to the earth's atmosphere and contributing to climate change. These two gasses contributed up to 92% of all the greenhouse gas emissions in 2015 (epa.gov). From an industrial pe…
  • College: College of Arts & Sciences
  • Inventors: Parquette, Jonathan; Satagopan, Sriram; Sun, Yuan; Tabita, Fred
  • Licensing Officer: Flammang, Ann Marie

Thermogenic Biologicals Treatment of Obesity and Improvement of Insulin Resistance
TS-037746 — Innovative thermogenic biologicals, methods of delivery, and combinational therapy for the treatment of abdominal obesity
Obesity as a result of an increase in intra-abdominal (or visceral) fat is an independent risk factor for major diseases such as type 2 diabetes and cardiovascular diseases due to increases in insulin resistance and chronic inflammation. Accumulation of intra-abdominal fat, even in non-­obese …
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: Flammang, Ann Marie

Antisense Morpholino Treatment to Increase SMN Levels and Treat Spinal Muscular Atrophy
TS-037648 — A treatment for spinal muscular atrophy.
Spinal Muscular Atrophy (SMA) is caused by deletion or mutation of SMN1 and retention of SMN2, this in turn leads to reduced levels of the full SMN protein. SMA is the second leading cause of neuromuscular disease, and many people living with SMA need round-the-clock care from their families and a…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Porensky, Paul
  • Licensing Officer: Flammang, Ann Marie

Drug Derivatives and Drug Carriers for Targeting Tumor Cells via Caveolin-1/Caveolae
TS-037232 — The use of plasma membrane proteins as a biomarker and drug transport mechanism for cancer patients.
According to the National Cancer Institute, there are approximately 15 million people living with cancer in the United States. Current cancer treatments include chemotherapy, surgical intervention, radiation therapy and targeted immunological and hormonal treatments. Chemotherapy treatments travel…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Self-Assembly of Therapeutic-Agent Nanostructures
TS-014812 — An improved delivery mechanism has been developed for hydrophobic drugs such as camptothecin which will increase chemotherapeutic efficacy.
Many cancer therapeutics exhibit extremely toxic side effects or have limited efficacy due to low bio-availability. Existing drug delivery technologies can add excessive mass to the therapeutic, grossly expanding the dosage necessary for response. Camptothecin (CPT) is a naturally occurring compou…
  • College: College of Arts & Sciences
  • Inventors: Parquette, Jonathan; Grinstaff, Mark; Kaplan, Jonah; Kim, Se Hye
  • Licensing Officer: Flammang, Ann Marie
PDF

Loading icon